ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06182072 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: ProAgio Dose Levels (DL) 1,2,3,4
DRUG: Gemcitabine, nab paclitaxel

Sponsor

ProDa BioTech, LLC

Collaborators

[object Object]
[object Object]